Novavax names new CEO

Stanley C. Erck, the former executive chairman of Novavax, Inc., has been appointed as the company's new president and chief executive officer.

Erck will remain as a member of Novavax's board of directors.

Erck served as president and CEO of Iomai Corporation from 2000 through 2008, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company.

Prior to joining Iomai, Erck was the president and CEO of Procept, a publicly-traded immunology company. He also served as vice president of corporate development at Integrated Genetics and in management positions within Baxter International.

Erck received his undergraduate degree from the University of Illinois and his masters in business administration from the University of Chicago Graduate School of Business.

Additionally, current Novavax board member James Young has been appointed to the position of chairman of the board.

Young joined the board n April 2010, bringing more than 30 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. He previously served as president of research and development at MedImmune.

Prior to his work at MedImmune, Young helped build the department of molecular genetics at Smith Kline & French Laboratories.

"As the company continues its transition into a commercial operation, we are pleased to have attracted high caliber professionals such as Stan and Jim to now take the leadership roles at Novavax," Gary Evans, who sits on Novavax's board of directors, said. "We expect these gentlemen will dynamically lead the Company and its vaccine candidates towards important worldwide products. Their strong leadership skills and broad experience in drug development will be invaluable to Novavax as the company works to advance its infectious disease pipeline of virus-like particle vaccine candidates."